Compare Stocks: ANAB, ORKA, MIRM, and ERAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$48.73 +1.3%	$52.67	$20.18 ▼ $72.36	$1.46B	0.76	582,829 shs	468,091 shs
ERAS Erasca	$14.39 +2.5%	$15.74	$2.11 ▼ $24.28	$5.03B	0.61	5.11 million shs	3.50 million shs
MIRM Mirum Pharmaceuticals	$80.39 -3.3%	$91.43	$63.23 ▼ $130.00	$5.22B	0.61	821,794 shs	788,215 shs
ORKA Oruka Therapeutics	$80.15 -1.2%	$89.62	$25.23 ▼ $115.51	$5.31B	-0.37	915,699 shs	513,993 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+4.55%	-5.74%	-10.01%	+44.81%
ERAS Erasca	0.00%	+7.47%	-0.90%	-24.70%	+533.92%
MIRM Mirum Pharmaceuticals	0.00%	+0.31%	-10.04%	-28.88%	+15.50%
ORKA Oruka Therapeutics	0.00%	+11.43%	-6.25%	-13.03%	+200.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$48.73 +1.3%	$52.67	$20.18 ▼ $72.36	$1.46B	0.76	582,829 shs	468,091 shs
ERAS Erasca	$14.39 +2.5%	$15.74	$2.11 ▼ $24.28	$5.03B	0.61	5.11 million shs	3.50 million shs
MIRM Mirum Pharmaceuticals	$80.39 -3.3%	$91.43	$63.23 ▼ $130.00	$5.22B	0.61	821,794 shs	788,215 shs
ORKA Oruka Therapeutics	$80.15 -1.2%	$89.62	$25.23 ▼ $115.51	$5.31B	-0.37	915,699 shs	513,993 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+4.55%	-5.74%	-10.01%	+44.81%
ERAS Erasca	0.00%	+7.47%	-0.90%	-24.70%	+533.92%
MIRM Mirum Pharmaceuticals	0.00%	+0.31%	-10.04%	-28.88%	+15.50%
ORKA Oruka Therapeutics	0.00%	+11.43%	-6.25%	-13.03%	+200.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.71	Moderate Buy	$77.79	59.63% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	53.52% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$148.19	84.34% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$128.91	60.83% Upside

Current Analyst Ratings Breakdown

Latest ANAB, ORKA, MIRM, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D) ➝ Sell (D-)
10/21/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$140.00 ➝ $145.00
10/19/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$151.00
10/14/2026	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$136.00 ➝ $156.00
10/13/2026	ORKA Oruka Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	MIRM Mirum Pharmaceuticals	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$146.00
10/12/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$137.00 ➝ $152.00
10/12/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$160.00 ➝ $184.00
10/12/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$195.00 ➝ $200.00
10/8/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$135.00 ➝ $155.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	6.21	N/A	N/A	$1.34 per share	36.37
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
MIRM Mirum Pharmaceuticals	$521.31M	10.01	$0.05 per share	1,576.92	$6.12 per share	13.14
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	9.07	20.14	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)

Latest ANAB, ORKA, MIRM, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ERAS Erasca	-$0.1301	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	ORKA Oruka Therapeutics	-$0.5994	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	ANAB AnaptysBio	-$1.84	N/A	N/A	N/A	$25.56 million	N/A
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.4869	N/A	N/A	N/A	$178.08 million	N/A
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
ERAS Erasca	N/A	8.29	8.29
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
ORKA Oruka Therapeutics	N/A	38.51	38.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
ERAS Erasca	67.78%
MIRM Mirum Pharmaceuticals	N/A
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
ERAS Erasca	14.20%
MIRM Mirum Pharmaceuticals	8.32%
ORKA Oruka Therapeutics	23.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.90 million	20.48 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	Optionable

ANAB, ORKA, MIRM, and ERAS Headlines

Recent News About These Companies

Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book Value

October 20, 2026 | finance.yahoo.com

BTIG Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)

October 19, 2026 | theglobeandmail.com

BTIG Research Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

October 19, 2026 | americanbankingnews.com

Oruka Therapeutics' (ORKA) "Buy" Rating Reiterated at BTIG Research

October 19, 2026 | marketbeat.com

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

October 18, 2026 | seekingalpha.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $523,670.00 in Stock

October 18, 2026 | americanbankingnews.com

Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares of Stock

October 16, 2026 | insidertrades.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,000 Shares of Company Stock

October 15, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 9,999 Shares of Company Stock

October 14, 2026 | americanbankingnews.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $805,919.40 in Stock

October 14, 2026 | insidertrades.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 9,999 Shares of Stock

October 13, 2026 | marketbeat.com

ORKA-002 Phase 1 Milestone: What Oruka’s First-in-Human Trial Means for Investors

October 9, 2026 | tipranks.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Has Average Target Price of $128.91 According to Analysts

October 8, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Shares Down 4.3% - Time to Sell?

October 6, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in Stock

October 3, 2026 | insidertrades.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in Stock

October 2, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Co-Diagnostics (CODX)

September 25, 2026 | theglobeandmail.com

Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

September 24, 2026 | theglobeandmail.com

Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says

September 24, 2026 | finance.yahoo.com

ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors

September 24, 2026 | tipranks.com

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

September 24, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, ORKA, MIRM, and ERAS Company Descriptions

AnaptysBio NASDAQ:ANAB

$48.73 +0.63 (+1.31%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$48.44 -0.29 (-0.60%)

As of 10/23/2026 07:30 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Erasca NASDAQ:ERAS

$14.39 +0.35 (+2.49%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$14.10 -0.29 (-1.99%)

As of 10/23/2026 07:55 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$80.39 -2.71 (-3.26%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$81.50 +1.11 (+1.38%)

As of 10/23/2026 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oruka Therapeutics NASDAQ:ORKA

$80.15 -1.00 (-1.23%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$80.28 +0.13 (+0.16%)

As of 10/23/2026 07:30 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, ORKA, MIRM, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, ORKA, MIRM, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, ORKA, MIRM, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, ORKA, MIRM, and ERAS Company Descriptions

AnaptysBio NASDAQ:ANAB

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, ORKA, MIRM, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, ORKA, MIRM, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, ORKA, MIRM, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, ORKA, MIRM, and ERAS Company Descriptions

AnaptysBio NASDAQ:ANAB

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools